PainChek To Accelerate UK Sales Of Pain Assessment App With Nourish Care

PainChek Ltd (ASX: PCK) is the developer of the world’s first regulatory-cleared medical device for the assessment of pain, known as the PainChek® app.

The ability of the app to develop markers that can identify pain is a singular advantage for those with serious conditions that inhibit self-reporting of pain.

It can also identify and detect six facial action units indicative of pain in infants aged one month to 12 months.

Deal details

The company has established a reseller agreement with Nourish Care, a leading UK care management software provider.

The deal should quickly lead to new sales in the UK as the PainChek® digital pain assessment app will be available directly through Nourish’s current client base.

This includes home care, disability, and the 500,000 aged care bed market.

The app is available on smartphones and tablets and combines PainChek’s AI pain assessment tool.

This automates the multidimensional pain assessment process.

For Nourish it is a win, it can activate PainChek® immediately with the touch of a button.

Its clients, whether new or existing, can easily benefit from better, resident-focused care, which is great for all involved.

About PainChek

The app has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom.

An FDA review in the United States is in progress.

PainChek® has contracts with over 1,000 aged care facilities, with more than 4,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

PainChek® is already contracted to be licensed for use across ~25,000 beds in 600 UK aged care facilities, where there are currently 900,000 people living with dementia, projected to rise to 1.6 million by 2040.

In Australia, PainChek’s commercial licences cover over 57,000 beds and 790 aged care homes, over 32% of the total domestic market and growing with a current retention rate of 92%.

The company is also working with existing Australian Aged Care providers and clients to extend access to the technology into Retirement Living & Home Care – significantly expanding market size and opportunity.

Earlier this month PainChek completed a $5 million raising at $0.0251 a share.



Articles of Interest